# Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Source: https://onco.cc/trials/nct04581473/  
OnCo record `nct04581473` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.

## Summary

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection is a phase 1/2 interventional study registered as NCT04581473 by CARsgen Therapeutics Co., Ltd., with 192 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2024-10-18. Interventions recorded: CT041 autologous CAR T-cell injection and Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04581473
- Phase: 1/2
- Setting: An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
- Sponsor: CARsgen Therapeutics Co., Ltd.
- Enrolled: 192

## Sources

- ClinicalTrials.gov NCT04581473: https://clinicaltrials.gov/study/NCT04581473

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)

---
JSON: https://onco.cc/api/v1/entities/nct04581473.json